心脉通胶囊治疗原发性高血压有效性及安全性的Meta分析  

The Efficacy and Safety of Xinmaitong Capsules in the Treatment of Essential Hypertension:a Meta-analysis

作　　者：曹刚 戴小华[2] 杨帆[2] 王银燕[2] 付军[2] 梁国庆[2] 邵正斌[2] 董梅[2] 袁良[2] 冉永玲 CAO Gang;DAI Xiaohua;YANG Fan;WANG Yinyan;FU Jun;LIANG Guoqing;SHAO Zhengbin;DONG Mei;YUAN Liang;RAN Yongling(Anhui University of Chinese Medicine,Hefei 230031,Anhui,China;First Affiliated Hospital of Anhui University of Chinese Medicine/Institute of Cardiovascular Diseases,Anhui Academy of Chinese Medical Sciences,Hefei 230031,Anhui,China)

机构地区：[1]安徽中医药大学,合肥230031 [2]安徽中医药大学第一附属医院/安徽省中医药科学院心血管病研究所,合肥230031

出　　处：《中西医结合心脑血管病杂志》2020年第19期3153-3160,共8页Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease

基　　金：安徽省高等学校自然科学研究重大项目(No.KJ2017ZD21)。

摘　　要：目的系统评价心脉通胶囊治疗原发性高血压的临床疗效及安全性。方法计算机检索中国知网(CNKI)、万方数据库、维普数据库(VIP)、中国生物医学文献数据库、中国学术期刊网络出版总库(CAJD)、中国科技期刊数据库(CSTJ)、PubMed、The Cochrane Library自建库以来至2018年9月公开发表的心脉通胶囊治疗原发性高血压的随机对照试验(RCT),筛选纳入文献后,采用Review Manger 5.3软件进行荟萃分析。结果心脉通胶囊(试验组)与西药常规治疗组(对照组)比较,试验组可提高临床疗效[OR=3.95,95%CI(2.48,6.28),P<0.00001],降低收缩压水平[MD=-12.36,95%CI(-18.74,-5.99),P=0.0001],降低舒张压水平[MD=-5.41,95%CI(-7.08,-3.74),P<0.00001],降低心脑血管事件发生率[OR=0.23,95%CI(0.09,0.54),P=0.0009],降低总胆固醇[MD=-0.83,95%CI(-1.07,-0.58),P<0.00001],降低低密度脂蛋白胆固醇(LDL-C)[MD=-1.01,95%CI(-1.98,-0.03),P=0.04],提升高密度脂蛋白胆固醇(HDL-C)[MD=0.21,95%CI(0.07,0.36),P=0.004],三酰甘油比较差异无统计学意义(P>0.05),降低全血高切黏度水平[MD=-0.76,95%CI(-1.05,-0.46),P<0.00001],降低全血低切黏度水平[MD=-1.02,95%CI(-1.32,-0.72),P<0.00001],血浆黏度方面比较差异无统计学意义(P>0.05),不良反应发生率低[OR=0.28,95%CI(0.13,0.61),P=0.001]。结论现有证据表明,心脉通胶囊可提高原发性高血压临床疗效,有效辅助降压,改善血脂水平及血液流变学指标,减少心脑血管事件发生,具有良好的临床安全性。Objective To evaluate the efficacy and safety of Xinmaitong capsules(XMTC)in the treatment of essential hypertension.Methods Randomized controlled trials(RCT)about XMTC in the treatment of essential hypertension published before September 2018 were retrieved from Chinese and foreign databases,such as China National Knowledge Infrastructure(CNKI),Wanfang database,VIP database,Chinese Biomedical Literature database(CBM),China Academic Journal Network Publishing Database(CAJD),China Science and Technology Journal database(CSTJ),PubMed,and Cochrane library.The literatures were analyzed by Review Manger 5.3 software.Results Comparing with the conventional treatment group of western medicine,XMTC could improve the clinical efficacy[OR=3.95,95%CI(2.48,6.28),P<0.00001],discrease diastolic blood Pressure[MD=-5.41,95%CI(-7.08,-3.74),P<0.00001],reduce the incidence rate of cardiovascular and cerebrovascular diseases[OR=0.23,95%CI(0.09,0.54),P=0.0009],improve cholesterol levels[MD=-0.83,95%CI(-1.07,-0.58),P<0.00001]with the decrease in LDL-C levels[MD=-1.01,95%CI(-1.98,-0.03),P=0.04]and an increase in HDL-C[MD=0.21,95%CI(0.07,0.36),P=0.004],reduce whole blood high shear visozity levels[MD=-0.76,95%CI(-1.05,-0.46),P<0.00001],reduce whole blood low shear viscosity levels[MD=-1.02,95%CI(-1.32,-0.72),P<0.00001].There was no significant difference in plasma viscosity between two groups(P>0.05).The incidence of adverse reactions was low[OR=0.28,95%CI(0.13,0.61),P=0.001].Conclusion Current evidences shows that the XMTC can improve the clinical efficacy of essential hypertension,effectively assist in lowering blood pressure,improve blood lipid levels and blood rheology indicators,reduce the occurrence of cardiovascular and cerebrovascular events,and have better.

关 键 词：原发性高血压 心脉通胶囊 随机对照试验 META分析 

分 类 号：R544.1[医药卫生—心血管疾病] R289.5[医药卫生—内科学]